Utilizing our Boltbody™ ISAC approach and myeloid biology expertise, we have a built a robust pipeline of immune-stimulating, myeloid-engaging therapeutics.
HER2+ Colorectal, Endometrial, Gastroesophageal Cancer
HER2+ Metastatic Breast Cancer*
Human epidermal growth factor receptor 2, or HER2, is a gene that encodes a protein that promotes cell growth and differentiation. HER2 protein overexpression and gene amplification have been documented across multiple cancers. Previous targeting of HER2 has had a major impact on the subset of patients with HER2-expressing breast and gastric cancer, but there remains a significant amount of work to be done highlighted by a significant individual and global patient need.
Our lead product candidate, BDC-1001, currently advancing into a Phase 2 clinical trial, seeks to improve therapeutic outcomes for patients with HER2-positive colorectal, endometrial, gastroesophageal and metastatic breast cancer.
Our Myeloid Modulator Platform reawakens myeloid cells to attack tumor cells. We identified monoclonal antibodies that are capable of binding to and agonizing a novel cell surface protein (referred to as Dectin-2) on tumor-supportive macrophages. The activation of these macrophages results in the production of pro-inflammatory cytokines, consistent with the characteristics of tumor-destructive macrophages. Dectin-2 may have the potential to reprogram tumor-supportive macrophages into tumor-destructive macrophages to elicit a productive anti-tumor immune response.
Range of Solid Tumors
Bispecific Boltbody ISACs
† Collaboration using Bristol-Myers Squibb’s PD-1 inhibitor nivolumab
§ Collaboration using Roche’s HER2 antagonist pertuzumab